• Mejo C Korah Student, Nandha college of Pharmacy
  • Junaid Rahman Pv Department of Pharmacology, Nandha College of Pharmacy and Research Institute, Erode, Tamil Nadu, India.
  • Rajeswari R Department of Pharmacology, Nandha College of Pharmacy and Research Institute, Erode, Tamil Nadu, India.
  • Ahana Behanan Department of Pharmacology, Nandha College of Pharmacy and Research Institute, Erode, Tamil Nadu, India.
  • Elizabeth Phoeba Paul Department of Pharmacology, Nandha College of Pharmacy and Research Institute, Erode, Tamil Nadu, India.
  • Sivakumar T Department of Pharmacology, Nandha College of Pharmacy and Research Institute, Erode, Tamil Nadu, India.


Vitamins are essential to our day to day life. Its shortage in our body can cause many disorders, decreased enzyme activities also affects the genetic factors. Vitamins should be supplied through the diet in the required amount. If it is not supplied properly, vitamin tablets will be prescribed. And also vitamin tablets are the co-medication for therapies like anticancer, anti tubercular, anti viral anti HIV treatments. Many news papers reported that vitamin therapies are causing major health problems like nephro/ urolithiasis, it can increases mortality rates in smokers by increasing the risk of lung cancer, it can cause abortion when it is taken during pregnancy. Thus here we reviewed the adverse effects of vitamin therapy from various reported cases, books, instructions provided from various health organizations and also news papers and magazines. It can help health professionals to control and monitor the vitamin therapies and make awareness about the adverse effects and possible side effects of regular vitamin uptake to society.

Keywords: Vitamin, Adverse effects, Toxicity, Side effects

Author Biography

Mejo C Korah, Student, Nandha college of Pharmacy
Belongs to department of Pharmacology, Nandha college of Pharmacy


2. Carroll Lutz, Karen Przytulski. Nutrition and Diet Therapy, Fifth edition Chapter-7 Vitamins-2011. Pg No 90-112.
3. The Merck Manual: Nutritional Disorders: Vitamin Introduction.
4. Vitamin and Mineral Supplement Fact Sheets Vitamin A. 5 june,2013.
5. Dietary Reference Intakes for Vitamin A, Vitamin K, 2001.
6. Bronstein, AC et al., "2008 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 26th Annual Report". Clinical Toxicology 2009 : 47 (10): 911–1084.
7. 5PNkE&Ic=en-IN&s=1&m=306&ts=1438102313&sig=AKQ9UOXSAz9Msqo VsY99AQFrUQs7vvKjA.
8. Fennema, Owen. Fennema's Food Chemistry. CRC Press Taylor & Francis 2008 :454–455.
9. Sommer, A., and K. P. West, Jr.. Vitamin A deficiency: health, survival and vision. Oxford University Press, New York. 1996.
10. Eduardo Villamor and Wafaie W. Fawzi, Effects of Vitamin A Supplementation on Immune Responses and Correlation with Clinical Outcomes. Departments of Nutrition1 and Epidemiology, 2 Harvard School of Public Health, Boston, Massachusetts.
13. Kristina L Penniston and Sherry A Tanumihardjo. Review article on The acute and chronic toxic effects of vitamin A, Am J Clin Nutr 2006;83:191–201

14. Myhre AM, Carlsen MH, Bohn SK, Wold HL, Laake P, Blomhoff R.Water-miscible, emulsified, and solid forms of retinol supplements are more toxic than oil-based preparations. Am J Clin Nutr 2003;78:1152–9.
15. Malvasi, A, et al: Possible long-term teratogenic effect of isotretinoin in pregnancy. Eur Rev Med Pharmacol Sci 2009:13:393.
16. Robin D. Clugston and William S. Blaner. Review on The Adverse Effects of Alcohol on Vitamin A Metabolism. Department of Medicine and Institute of Human Nutrition College of Physicians and Surgeons, Columbia University, New York 2012.
17. Lieber, C.S. Relationships between nutrition, alcohol use, and liver disease. Alcohol. Res. Health 2003, 27, 220–231.
18. Halsted, C.H. Nutrition and alcoholic liver disease. Semin. Liver Dis. 2004, 24, 289–304.
19. Roncone, D.P. Xerophthalmia secondary to alcohol-induced malnutrition. Optometry 2006, 77,124–133.
20. Ross,DA:Recommendations for vitamin A supplementation. J Nutr 132:2902S,2002.
21. Huiming,Y,Chaomin,W,and Meng,M : Vitamin A for treating measles in children. Cochrane Database Syst Rev 2005: 4:CD001479,.
22. Robert agabio (2004). Thiamine administration in alcohol dependent patient oxford journals.
23. Ambrose ML,Bowden sc,$Whelan. g.thiamine treatment and working memory function of alcohol dependent people:preliminary findings.alcoholism.clinical and experimental Research 2001:25(1)112-116.
24. Peter R Martin MD,Charles K Singleton,Ph.D,Susanne Hiller –Sturmhotel,The role of thiamine deficiencyin alcoholic brain disease.
25. Singleton CK and Martin PR .Molecular mechanism of thiamine utilization. Current Molecular medicine 2001: 1(2):197-207.
26. Balakumar P, Rohilla A, Krishan P, Solairaj P, Thangathirupathi A: The multifaceted therapeutic potential of benfotiamine. Pharmacol Res 2010, 61:482-488.
27. Donnino M, Carney E, Cocchi M, Barbash I: Thiamine deficiency in critically ill patients with sepsis. J Crit Care 2010, 25:576-581.
28. Donnino MW, Cocchi MN, Smithline H, Carney E, Chou PP, Salciccioli J: Coronary artery bypass graft surgery depletes plasma thiamine levels. Nutrition 2010: 26: 133-136.
29. Soukoulis V, Dihu JB, Sole M, Anker SD, Cleland J, Fonarow GC, Metra M, Pasini E, Strzelczyk T, Taegtmeyer H, Gheorghiade M: Micronutrient deficiencies an unmet need in heart failure. J Am Coll Cardiol 2009, 54:1660-1673.
30. Hartung E, Freye E. The effect of thiamine on the contractile responses of the isolated heart muscle.Acta Vitaminol Enzymol. 1980 ;2:3–5.
31. Meador K, Loring D, Nichols M, Zamrini E, Rivner M, Posas H, Thompson E, Moore E. Preliminary findings of high-dose thiamine in dementia of Alzheimer's type. J Geriatr Psychiatry Neurol.1993; 6:222–229.
32. Wolfson SK, Ellis S. Thiamine: toxicity and ganglionic blockade. Fed Proc. 1954;13:418.
33. Meador K, Loring D, Nichols M, Zamrini E, Rivner M, Posas H, Thompson E, Moore E:Preliminary findings of high-dose thiamine in dementia of Alzheimer's type. JGeriatr Psychiatry Neurol 1993, 6:222-229.
34. Alkhalaf A, Klooster A, van Oeveren W, Achenbach U, Kleefstra N, Slingerland RJ, Mijnhout GS, Bilo HJ, Gans RO, Navis GJ, Bakker SJ: A double-blind, randomized, placebo-controlled clinical trial on benfotiamine treatment in patients with diabetic nephropathy. Diabetes Care 2010, 33:1598-1601.
35. Stracke H, Gaus W, Achenbach U, Federlin K, Bretzel RG: Benfotiamine in diabetic polyneuropathy (BENDIP): results of a randomised, double blind, placebo-controlled clinical study. Exp Clin Endocrinol Diabetes 2008, 116:600-605.
36. Thornalley PJ: The potential role of thiamine (vitamin B1) in diabetic complications. Curr Diabetes Rev 2005, 1:287-298.
37. Gropper,SS,Smith,JL,and Groff,JL:Advanced Nutrition And Human Metabolism,ed 5.Wadsworth, Belmont,CA,2009.
38. Boehnke C, Reuter U, Flach U, Schuh-Hofer S, Einhaupl KM, Arnold G. High-dose riboflavin treatment is efficacious in migraine prophylaxis. Eur J Neurol 2004;11:475-477.
39. Jernigan HM Jr., Role of hydrogen peroxide in riboflavin-sensitized photodynamic damage to cultured rat lenses, Exp Eye Res 1985 Jul;41(1):121-9.
40. Kale H, Harikumar P, Kulkarni SB, Nair PM, Netrawali MS, Assessment of the genotoxic potential of riboflavin and lumiflavin. B. Effect of light, Mutat Res 1992 Nov; 298(1):17-23.
41. Silva E, Salim-Hanna M, Edwards AM, Becker MI, De Ioannes AE, A light-induced tryptophan-riboflavin binding: biological implications, Adv Exp Med Biol 1991;289:33-48.
42. Chessex P, Lavoie JC, Rouleau T, Brochu P, St-Louis P, Levy E, Alvarez F, Photooxidation of parenteral multivitamins induces hepatic steatosis in a neonatal guinea pig model of intravenous nutrition, Pediatr Res 2002 Dec;52(6):958-63.
43. Bhatia J, Moslen MT, Haque AK, McCleery R, Rassin DK, Total parenteral nutrition-associated alterations in hepatobiliary function and histology in rats: is light exposure a clue. Pediatr Res 1993 May;33(5):487-92.
44. Edwards AM, Silva E, Effect of visible light on selected enzymes, vitamins and amino acids, J Photochem Photobiol B 2001 Oct;63(1-3):126-31.
45. Frati E, Khatib AM, Front P, Panasyuk A, Aprile F, Mitrovic DR, Degradation of hyaluronic acid by photosensitized riboflavin in vitro. Modulation of the effect by transition metals, radical quenchers, and metal chelators, Free Radic Biol Med 1997;22(7):1139-44.
46. Riemschneider S, Podhaisky HP, Klapperstuck T, Wohlrab W, Relevance of reactive oxygen species in the induction of 8-oxo-2'-deoxyguanosine in HaCaT keratinocytes, Acta Derm Venereol 2002;82(5):325-8.
47. Oikawa S, Tada-Oikawa S, Kawanishi S, Site-specific DNA damage at the GGG sequence by UVA involves acceleration of telomere shortening, Biochemistry 2001 Apr 17;40(15):4763-8.
48. Salet C, Moreno G, Photodynamic action increases leakage of the mitochondrial electron transport chain, Int J Radiat Biol 1995 Apr;67(4):477-80.
49. Cho KS, Lee EH, Choi JS, Joo CK, Reactive oxygen species-induced apoptosis and necrosis in bovine corneal endothelial cells, Invest Ophthalmol Vis Sci 1999 Apr;40(5):911-9.
50. Stone NJ, Robinson J, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2013 November 12.
51. Catapano AL, Reiner Z, De Backer G, et al. ESC/EAS guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).Atherosclerosis 2011;217:Suppl 1:S1-S44.
52. Andersson RG, Aberg G, Brattsand R, Ericsson E, Lundholm L. Studies on the mechanism of flush induced by nicotinic acid. Acta Pharmacol Toxicol (Copenh) 1977;41:1–10.
53. Morgan JM, Capuzzi DM, Guyton JR. A new extended-release niacin (Niaspan): efficacy, tolerability, and safety in hypercholesterolemic patients. Am J Cardiol. 1998;82:29U–34U.
54. Guyton JR, Bays HE. Safety considerations with niacin therapy. Am J Cardiol 2007;99:22C-31C.
55. Nagakawa Y, Orimo H, Harasawa M. The anti-platelet effect of niceritrol in patients with arteriosclerosis and the relationship of the lipid-lowering effect to the anti-platelet effect.Thromb Res 1985;40:543-553.
56. Philipose S, Konya V, Lazarevic M, et al. Laropiprant attenuates EP3 and TP prostanoid receptor-mediated thrombus formation. PLoS One 2012;7:e40222-e40222.
57. Chesney CM, Elam MB, Herd JA, et al. Effect of niacin, warfarin, and antioxidant therapy on coagulation parameters in patients with peripheral arterial disease in the Arterial Disease Multiple Intervention Trial (ADMIT). Am Heart J 2000;140:631-636.
58. Serebruany V, Malinin A, Aradi D, Kuliczkowski W, Norgard NB, Boden WE. The in vitro effects of niacin on platelet biomarkers in human volunteers. Thromb Haemost2010;104:311-317.
59. The AIM-HIGH Investigators. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med2011;365:2255-2267[Erratum, N Engl J Med 2012;367:189.]
60. Clofibrate and niacin in coronary heart disease.JAMA 1975;231:360-381
61. Morgan JM, Capuzzi DM, Guyton JR. A new extended-release niacin (Niaspan): efficacy, tolerability, and safety in hypercholesterolemic patients. Am J Cardiol 1998;82:29U-34U, 39U
62. HPS2-THRIVE Collaborative Group. HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. Eur Heart J 2013;34: 1279-1291.
63. Effects of Extended-Release Niacin with Laropiprant in High-Risk Patients)The HPS2-THRIVE Collaborative Group N Engl J Med 2014; 371:203.
64. Hendler SS, Rorvik DR, eds. PDR for Nutritional Supplements. 2nd ed. Montvale: Thomson Recuters; 2008.
65. Herbst RA, Uter W, Pirker C, Geier J, Frosch PJ. Allergic and non-allergic periorbital dermatitis: patch test results of the Information Network of the Departments of Dermatology during a 5-year period. Contact Dermatitis. 2004;51(1):13-19.
66. Schmuth M, Wimmer MA, Hofer S, et al. Topical corticosteroid therapy for acute radiation dermatitis: a prospective, randomized, double-blind study. Br J Dermatol. 2002;146(6):983-991.
67. Flodin N. Pharmacology of micronutrients. New York: Alan R. Liss, Inc.; 1988.
68. Debourdeau PM, Djezzar S, Estival JL, Zammit CM, Richard RC, Castot AC. Life-threatening eosinophilic pleuropericardial effusion related to vitamins B5 and H. Ann Pharmacother. 2001;35(4):424-426.
69. Said HM, Ortiz A, McCloud E, Dyer D, Moyer MP, Rubin S. Biotin uptake by human colonic epithelial NCM460 cells: a carrier-mediated process shared with pantothenic acid. Am J Physiol. 1998;275(5 Pt 1):C1365-1371.
70. Chirapu SR, Rotter CJ, Miller EL, Varma MV, Dow RL, Finn MG. High specificity in response of the sodium-dependent multivitamin transporter to derivatives of pantothenic acid. Curr Top Med Chem. 2013;13 (7):837-842.
71. Effects of a leucine and pyridoxine-containing nutraceutical on body weight and composition in obese subjects Michael B Zemel and Antje Bruckbauer v.6; 2013 Diabetes Metab Syndr Obes. 2013; 6: 309–315.
72. Hunt AD, Jr, Stokes J, Jr, McCrory WW, Stroud HH.. Pyridoxine dependency: Report of a case of intractable convulsions in an infant controlled by pyridoxine. Pediatrics. 1954; 13:140-145.
73. Roman ,GC:Nutritional disorders of the nervous system.In Shills,ME,et al(eds):Modern Nutrition in Health and Disease,ed 10.Lippincott Williams &Wilkins,Philadelphia,2006.
74. Scott JM, Dinn JJ, Wilson NVB, et al. Pathogenesis of subacute combined degeneration: a result of methyl group deficiency. Lancet1981; 334–7.
75. Miller AA, Goff D, Webster RA. Predisposition of laboratory animals to epileptogenic activity of folic acid. In: Botez MI, Reynolds EH, eds. Folic acid in neurology, psychiatry, and internal medicine. New York, Raven Press, 1979:331–4.
76. O'Donnell RA, Leach MJ, Miller AA. Folic acid induced kindling in rats: changes in brain amino acids. In: Blair JA, ed. Chemistry and biology of pteridines. Berlin: Walter de Gruyter,1983:801–5.
77. Davies J, Watkins JC. Facilitatory and direct excitatory effects of folate and folinate on single neurons of cat cerebral cortex. Biochem Pharmacol1973;1667–8.
78. Hill RG, Miller AA. Antagonism by folic acid of presynaptic inhibition in the rat cuneate nucleus. Br J Pharmacol1974;50:425–7.
79. Hunter R, Barnes J, Oakley MF, et al. Toxicity of folic acid given in pharmacological doses to healthy volunteers. Lancet1970;i:61.
80. Fareena Bilwani, Salman N. Adil, Usman Sheikh, Ayesha Humera, Mohammad Khurshid, Anaphylactic Reaction after Intramuscular Injection of Cyanocobalamin (Vitamin B12): a Case Report: Department of Pathology, The Aga Khan University Hospital, Karachi.
81. Baly F, Sager MF, Hirth C. IGE-mediated reaction to hydroxycobalamininjection in-patient with pernicious anemia. Lancet1992; 339:1535-6.
82. Wulffele MG, Kooy A, Lehert P, Bets D, Ogterop JC, Borger van der Burg B, et al. Effects of short-term treatment with metformin on serum concentrations of homocysteine, folate and vitamin B12 in type 2 diabetes mellitus: a ran-domised, placebo-controlled trial. J Intern Med. 2004;254:455–63.
83. Meister A (April 1994). "Glutathione-ascorbic acid antioxidant system in animals" (PDF). J. Biol. Chem. 269 (13): 9397–400.
84. Michels A, Frei B (2012). "Vitamin C". In Caudill MA, Rogers M. Biochemical, Physiological, and Molecular Aspects of Human Nutrition (3 ed.). Philadelphia: Saunders. pp. 627–654.
85. Hardie LJ, Fletcher TC, Secombes CJ (1991). "The effect of dietary vitamin C on the immune response of the Atlantic salmon (Salmo salar L.)". Aquaculture 95 (3–4): 201–14.
86. Food and Nutrition Board, Institute of Medicine. Dietary reference intakes for vitamin C, vitamin E, selenium, and carotenoids. A report of the Panel on Dietary Antioxidants and Related Compounds, Subcommittees on Upper Reference Levels of Nutrients and Interpretation and Uses of Dietary Reference Intakes, and the Standing Committee on the Scientific Evaluation of Dietary Reference Intakes. Washington, DC: National Academy Press, 2000.
87. Luo J, Shen L, Zheng D (2014). "Association between vitamin C intake and lung cancer: a dose-response meta-analysis". Sci Rep 4: 6161.
88. Ye Y, Li J, Yuan Z (2013). "Effect of antioxidant vitamin supplementation on cardiovascular outcomes: a meta-analysis of randomized controlled trials". PLoS ONE 8 (2): e56803.doi:10.1371/journal.pone.0056803.
89. Rosenbaum CC, O'Mathúna DP, Chavez M, Shields K (2010). "Antioxidants and antiinflammatory dietary supplements for osteoarthritis and rheumatoid arthritis". Altern Ther Health Med 16 (2): 32–40.
90. Cortés-Jofré M, Rueda JR, Corsini-Muñoz G, Fonseca-Cortés C, Caraballoso M, Bonfill Cosp X (2012). "Drugs for preventing lung cancer in healthy people". Cochrane Database Syst Rev.
91. Crichton GE, Bryan J, Murphy KJ (September 2013). "Dietary antioxidants, cognitive function and dementia--a systematic review". Plant Foods Hum Nutr 68 (3): 279–92.
92. Li FJ, Shen L, Ji HF (2012). "Dietary intakes of vitamin E, vitamin C, and β-carotene and risk of Alzheimer's disease: a meta-analysis". J. Alzheimers Dis. 31 (2): 253–8.
93. Douglas RM, Hemilä H, Chalker E, Treacy B (2007). Hemilä, Harri, ed. "Vitamin C for preventing and treating the common cold". Cochrane Database Syst Rev (3): CD000980.
94. Heimer KA, Hart AM, Martin LG, Rubio-Wallace S (May 2009). "Examining the evidence for the use of vitamin C in the prophylaxis and treatment of the common cold". J Am Acad Nurse Pract 21 (5): 295–300.
95. Chylack LT Jr, Brown NP, Bron A, et al. The Roche European American Cataract Trial (REACT): a randomized clinical trial to investigate the efficacy of an oral antioxidant micronutrient mixture to slow progression of age-related cataract. Ophthalmic Epidemiol 2002;9:49–80.
96. Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch Ophthalmol 2001;119:1417–36.
97. Brown BG, Zhao XQ, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001; 345:1583–92.
98. H E Sauberlich: Pharmacology of Vitamin C. Annual Review of Nutrition. 1994 : Vol. 14: 371-391.
99. Toxicological evaluation of some food additives including anticaking agents, antimicrobials, antioxidants, emulsifiers and thickening agents". World Health Organization. July 4, 1973. Retrieved April 13, 2007.
100. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering therapy and of antioxidant vitamin supplementation in a wide range of patients at increased risk of coronary heart disease death: early safety and efficacy experience. Eur Heart J 1999;20:725–41..
101. Fleming DJ, Tucker KL, Jacques PF, Dallal GE, Wilson PW, Wood RJ (December 2002)."Dietary factors associated with the risk of high iron stores in the elderly Framingham Heart Study cohort". The American Journal of Clinical Nutrition 76 (6): 1375–84.
102. Cook JD, Reddy MB (January 2001). "Effect of ascorbic acid intake on nonheme-iron absorption from a complete diet". The American Journal of Clinical Nutrition 73 (1): 93–8.
103. Sano M, Ernesto C, Thomas RG, et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer’s disease. The Alzheimer’s Disease Cooperative Study. N Engl J Med 1997;336:1216–22.
104. Rivers JM. Safety of high-level vitamin C ingestion. Int J Vitam Nutr Res Suppl 1989;30:95–102.
105. Diplock AT. Safety of antioxidant vitamins and beta carotene. Am J Clin Nutr 1995;62(suppl):1510S–6S.
106. Balcke P. Schmidt P, Zazgornik J, et al. Ascorbic acid aggravates secondary hyperoxalemia in patients on chronic hemodialysis. Ann Intern Med 1984;101:344–5.
107. Curhan GC, Willett WC, Rimm EB, et al. A prospective study of the intake of vitamins C and B6 and the risk of kidney stones in men. J Urol 1996;155:1847–51.
108. Hathcock JN. Vitamins and minerals: efficacy and safety. Am J Clin Nutr 1997;66:427–37.
109. Hoffer A. Ascorbic acid and kidney stones. Can Med Assoc J 1985;132:320.
110. Mashour S, Turner JF, Merrell R. "Acute renal failure, oxalosis, and vitamin C supplementation: a case report and review of the literature". Chest 2000: 118 (2): 561–3.
111. Food and Nutrition Board, Institute of Medicine. Dietary reference intakes for vitamin C, vitamin E, selenium, and carotenoids. A report of the Panel on Dietary Antioxidants and Related Compounds, Subcommittees on Upper Reference Levels of Nutrients and Interpretation and Uses of Dietary Reference Intakes, and the Standing Committee on the Scientific Evaluation of Dietary Reference Intakes. Washington, DC: National Academy Press, 2000.
112. Stein HB, Hasan A, Fox IH. Ascorbic acid-induced uricosuria. Ann Intern Med 1976;84:385–8.
113. Levine M, Conry-Cantilena C, Wang Y, et al. Vitamin C pharmacokinetics in healthy volunteers: evidence for a recommended dietary allowance. Proc Natl Acad Sci U S A 1996;93:3704–9.
114. Ovcharov R, Todorov S (1974). "[The effect of vitamin C on the estrus cycle and embryogenesis of rats]". Akusherstvo I Ginekologii͡a (in Bulgarian) 13 (3): 191–5.
115. Balion C, Griffith LE, Strifler L, et al. Vitamin D, cognition,and dementia: a systematic review and meta-analysis.Neurology 2012;79:1397–1405.
116. Annweiler C, Llewellyn DJ, Beauchet O. Low serum vitamin D concentrations in Alzheimer’s disease: a systematicreview and meta-analysis. J Alzheimers Dis 2013;33:659–674.
117. Annweiler C, Montero-Odasso M, Llewellyn DJ, Richard-Devantoy S, Duque G, Beauchet O. Meta-analysis ofmemory and executive dysfunctions in relation to vitaminD. J Alzheimers Dis 2013;37:147–171.
118. Dursun E, Gezen-Ak D, Yilmazer S. A novel perspectivefor Alzheimer’s disease: vitamin D receptor suppression byamyloid-b and preventing the amyloid-b induced alterationsby vitamin D in cortical neurons. J Alzheimers Dis2011;23:207–219.
119. answers /vitamin-d-toxicity/ faq-20058108.
120. Brøndum-Jacobsen P, Nordestgaard BG, Schnohr P, Benn M. 25-hydroxyvitamin D and symptomatic ischemic stroke: an original study and meta-analysis. Ann Neurol 2013; 73:38–47.
121. Dionne J; Abitbol, Carolyn L.; Flynn, Joseph T. (2012). "Hypertension in infancy: diagnosis, management, and outcome". Pediatr Nephrol 27: 17–32.
122. Hsu, J. J.; Tintut, Y.; Demer, L. L. "Vitamin D and Osteogenic Differentiation in the Artery Wall". Clinical Journal of the American Society of Nephrology 2008: 3 (5): 1542–7
123. Tuohimaa P. "Vitamin D and aging". The Journal of Steroid Biochemistry and Molecular Biology 2009: 114 (1–2): 78–84.
124. Keisala T, Minasyan A, Lou YR. "Premature aging in vitamin D receptor mutant mice". The Journal of Steroid Biochemistry and Molecular Biology 2009: 115 (3–5): 91–7.
127. Brigelius-Flohé R, Traber MG; Traber. "Vitamin E: function and metabolism".FASEB J. 1999: 13 (10): 1145–1155
128. Vitamin E — Health Professional Fact Sheet.., 2015.
129. Sen, Chandan K.; Khanna, Savita; Roy, Sashwati. "Tocotrienols: Vitamin E beyond tocopherols". Life Sciences 2006: 78 (18): 2088–98
130. Das S, Lekli I, Das M, Szabo G, Varadi J, Juhasz B, Bak I, Nesaretam K, Tosaki A, Powell SR, Das DK; Lekli; Das; Szabo; Varadi; Juhasz; Bak; Nesaretam; Tosaki; Powell; Das. "Cardioprotection with palm oil tocotrienols: comparison of different isomers".American journal of physiology. Heart and circulatory physiology 2008: 294 (2): H970–8.
132. ingredient name=vitamin%20e..
133. Higdon, "Vitamin K". Linus Pauling Institute, Oregon State University. Retrieved 12 April 2008.
134. Louis D Fiore, Michael A Scola, Colleen E Cantillon and Mary T Brophy, Anaphylactoid reactions to Vitamin K. Journal of thrombosis and thrombolysis. 2001175-183.
135. Ansell J, Hirsh J, Poller L, Bussey H, Jacobson A, Hylek E. "The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy". Chest 2004: (3 Suppl): 204S–233S.
136. Crowther MA; Douketis JD; Schnurr T; Steidl, L; Mera, V; Ultori, C; Venco, A; Ageno, W. "Oral vitamin K lowers the international normalized ratio more rapidly than subcutaneous vitamin K in the treatment of warfarin-associated coagulopathy. A randomized, controlled trial". Ann. Intern. Med. 2002:137 (4): 251–4.
137. Important Information to Know When You Are Taking: Warfarin (Coumadin) and Vitamin K, 2015.
138. Schurgers, L. J, Spronk, H. M. H, Soute, B. A. M, Schiffers, P. M, Demey, J. G Vermeer, C. "Regression of warfarin-induced medial elastocalcinosis by high intake of vitamin K in rats". Blood 2006: 109 (7): 2823–2831.
140. Moyer, VA. "Vitamin, Mineral, and Multivitamin Supplements for the Primary Prevention of Cardiovascular Disease and Cancer: U.S. Preventive Services Task Force Recommendation Statement". Annals of internal medicine 2014: 160 (8): 558–64.
141. Bjelakovic, Goran; Nikolova, D; Gluud, LL; Simonetti, RG; Gluud, C. "Mortality in Randomized Trials of Antioxidant Supplements for Primary and Secondary Prevention: Systematic Review and Meta-analysis". JAMA 2007: 297 (8): 842–57.
142. Sen, Chandan K.; Khanna, Savita; Roy, Sashwati. "Tocotrienols: Vitamin E beyond tocopherols". Life Sciences 2006: 78 (18): 2088–98.
978 Views | 518 Downloads
How to Cite
Korah, M. C., J. R. Pv, Rajeswari R, A. Behanan, E. P. Paul, and Sivakumar T. “ADVERSE EFFECTS AND SIDE EFFECTS ON VITAMIN THERAPY: A REVIEW”. Asian Journal of Pharmaceutical and Clinical Research, Vol. 10, no. 5, May 2017, pp. 19-26, doi:10.22159/ajpcr.2017.v10i5.17014.
Review Article(s)